- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04014569
Determination of Automated Multiple Insulin Dose Injections Settings Using the MDI/SMBG Advisor for Patients With Type 1 Diabetes -Data Collection, Observational & Proof of Concept Study
The MDI (Multiple Daily Injections) plus SMBG |(Self Monitoring Blood Glucose) Advisor (MPSA) is a software product that is designed to assist in insulin dosage decision making for subjects with T1DM using multiple daily injection and SMBG.
The study will focus on the development, validation and eventually testing of the MPSA algorithm use. The major objective of the project is to develop an algorithm that will be able to optimize treatment plan parameters of MDI patients who use SMBG as glucose monitoring method. The clinical study has two segments. Segment A is an observational study needed for the development of the algorithm (this segment was already completed at the time of the registration) and Segment B is a proof of concept interventional study to validate the algorithm's Safety and Efficacy.
Up to 20 patients using MDI and SMBG or Flash Glucose Monitoring (FGM) without using glucose trends will be enrolled to this proof of concept study. The study will evaluate the algorithm use for a period of 11 weeks. Post screening, patients will undergo a two weeks run-in period while using MDI and SMBG or FGM (patients that do not use FGM will be provided with blinded Libre Flash to be used during the run-in period and 2 weeks prior to arriving to end of study visit). Then, patients will undergo insulin treatment plan changes every week for 7 weeks. At the first 3 weeks insulin dose adjustments will be done for basal insulin dose only, week 4 will be without changes, and in the next 3 weeks the carbohydrate ratio will be amended. No recommendations will be given during the last two weeks of the study. These two weeks will be used for data analysis. Each recommendation of the Advisor will be approved by a physician before implementation. Glucose outcomes will be evaluated comparing the two weeks run-in period to the last two weeks of the study.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Petach-Tikva, Israel
- Schnider children medical center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Documented T1D for at least 1 year prior to study enrolment
- Subjects aged ≥ 14 years and up to 30 years
- A1c at inclusion ≥ 7 % and ≤ 10%
- Using MDI of Basal/bolus therapy - basal insulin either Glargine/Lantus or Tregludec insulin and bolus short acting insulin analogs either aspart/Novorapid or Lispro/Humalog
- Using SMBG or flash glucose monitoring (FGM/Libre) without using glucose trends
- BMI SDS - below the 97th percentile for age
- Subjects willing to follow study instructions
Exclusion Criteria:
- An episode of diabetic keto-acidosis within the month prior to study entry and/or severe hypoglycemia resulting in seizure or loss of consciousness in the month prior to enrolment
- Concomitant diseases/ treatment that influence metabolic control or any significant diseases /conditions including psychiatric disorders and substance abuse that in the opinion of the investigator is likely to affect the subject's ability to complete the study or compromise patient's safety
- Participation in any other interventional study
- Known or suspected allergy to trial products
- Female subject who is pregnant or planning to become pregnant within the planned study duration
- Subject needs to travel by air during the study duration
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MPSA Algorithm
Insulin dosing will be adjusted using the MPSA algorithm
|
Insulin dosing will be adjusted using the MPSA Algorithm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of sensor glucose readings within range of 70-180 mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of sensor glucose readings below 54 mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
HbA1c
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Number of Severe Hypoglycemia events
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Number of Diabetic Ketoacidosis events
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of sensor glucose readings below 70 mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Percentage of sensor glucose readings below 50mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Percentage of sensor glucose readings above 180mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Percentage of sensor glucose readings above 250mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Number of unexplained hyperglycemic events
Time Frame: Final visit (day42)
|
Final visit (day42)
|
Area above the curve of 180mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Area above the curve >180mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Area under the curve of 70mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Area under the curve <70mg/dl
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Mean sensor blood glucose
Time Frame: Final visit (day42)
|
Final visit (day42)
|
Glucose variability measured by SD (standard deviation)
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Number of recommendations for changes in settings per patient
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Number of recommendations for changes in setting per iteration
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Number of physician override advisor recommendations
Time Frame: Final visit (day 42)
|
Final visit (day 42)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RMC018718ctil
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on MPSA Algorithm
-
University of ArizonaUnknown
-
Samuel Lunenfeld Research Institute, Mount Sinai...Completed
-
University of California, San FranciscoEko Devices, Inc.CompletedAortic Valve Stenosis | Mitral Regurgitation | Heart Murmurs | Valvular Heart DiseaseUnited States
-
ResMedCompletedObstructive Sleep Apnea (OSA)Australia
-
Johann Wolfgang Goethe University HospitalHemoSonics LLCTerminatedHemorrhage | BleedingGermany
-
Ottawa Heart Institute Research CorporationActive, not recruitingMitral RegurgitationCanada
-
University of OxfordUnknownHeart Failure, SystolicUnited Kingdom
-
University of UtahRecruiting
-
Kıvanç AkçaHacettepe UniversityCompleted
-
Moorfields Eye Hospital NHS Foundation TrustCompletedGlaucoma | HealthyUnited Kingdom